CURRENT OPINION IN PHARMACOLOGY

Scope & Guideline

Exploring the Frontiers of Drug Discovery

Introduction

Delve into the academic richness of CURRENT OPINION IN PHARMACOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1471-4892
PublisherELSEVIER SCI LTD
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2001 to 2024
AbbreviationCURR OPIN PHARMACOL / Curr. Opin. Pharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

CURRENT OPINION IN PHARMACOLOGY serves as a platform for the dissemination of cutting-edge research and reviews in the field of pharmacology, emphasizing therapeutic innovations, mechanistic insights, and translational applications. The journal aims to bridge the gap between basic research and clinical practice, providing insights into emerging therapies and pharmacological strategies.
  1. Therapeutic Innovations:
    The journal focuses on novel therapeutic strategies and advancements in drug development across various medical fields, including oncology, neurology, and pain management.
  2. Mechanistic Insights:
    Emphasizing the understanding of biochemical and molecular mechanisms underlying drug action and disease pathology, the journal publishes studies that elucidate the pharmacodynamics and pharmacokinetics of new and existing drugs.
  3. Translational Research:
    CURRENT OPINION IN PHARMACOLOGY highlights the translation of laboratory findings into clinical applications, showcasing studies that connect preclinical research with potential therapeutic outcomes.
  4. Disease-Specific Pharmacology:
    The journal addresses pharmacological approaches tailored to specific diseases, including autoimmune disorders, metabolic syndromes, and neurodegenerative conditions.
  5. Interdisciplinary Approaches:
    Encouraging collaboration across disciplines, the journal publishes research that integrates pharmacology with fields such as genetics, immunology, and systems biology to develop comprehensive therapeutic strategies.
CURRENT OPINION IN PHARMACOLOGY has identified several trending and emerging themes that reflect the journal's responsiveness to contemporary challenges in pharmacology and therapeutics. These themes highlight areas of increasing research focus and potential for future developments.
  1. Pain Management Innovations:
    Recent publications demonstrate a growing emphasis on innovative pain management strategies, including the exploration of novel targets such as TRP channels and the endocannabinoid system, as well as biased signaling in analgesics.
  2. Targeted Therapies in Cancer:
    There is a surge in research focusing on targeted therapies for cancer treatment, particularly those that leverage advancements in understanding DNA damage repair and tumor microenvironment interactions.
  3. Neuropharmacology Advances:
    Emerging studies on neuropharmacology, particularly regarding neurodegenerative diseases and mental health, reflect a trend towards developing therapies that address complex neurological pathways.
  4. Personalized Medicine and Pharmacogenomics:
    The journal is increasingly featuring articles on personalized medicine approaches, highlighting the importance of pharmacogenomics in tailoring treatments to individual patient profiles.
  5. Integration of AI and Computational Methods:
    The incorporation of artificial intelligence and computational modeling in drug discovery and pharmacology is gaining traction, signifying a trend towards data-driven approaches in therapeutic development.

Declining or Waning

As the field of pharmacology evolves, certain themes and research areas have shown a decline in prominence within CURRENT OPINION IN PHARMACOLOGY. This section highlights those aspects that are becoming less common in recent publications.
  1. Traditional Pharmacotherapy:
    There is a noticeable decline in papers focused on traditional pharmacotherapy approaches, as the field shifts towards more innovative and personalized medicine strategies that incorporate genetic and molecular insights.
  2. General Reviews without Novel Insights:
    The journal has seen a reduction in general review articles that do not contribute new insights or perspectives, with a preference for publications that offer novel findings or advanced methodologies.
  3. Single-Drug Focus Studies:
    Research focusing solely on the efficacy of single drugs without considering combination therapies or multidisciplinary approaches appears to be less frequent, reflecting a broader trend towards integrative treatment strategies.
  4. Overemphasis on Mechanistic Studies:
    While mechanistic studies remain important, there is a declining interest in purely mechanistic explorations without translational implications, as researchers and clinicians increasingly seek studies with direct clinical relevance.

Similar Journals

European Journal of Pharmacology

Unveiling groundbreaking research in pharmacokinetics and toxicology.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

INVESTIGATIONAL NEW DRUGS

Exploring Breakthroughs in Investigational Drug Studies
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

BRITISH JOURNAL OF PHARMACOLOGY

Elevating research standards in the field of pharmacology.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Expert Review of Clinical Pharmacology

Exploring the frontiers of pharmacology for enhanced clinical practice.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

Journal of Pharmacological Sciences

Innovating drug development through impactful science.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Bridging Pharmacokinetics and Pharmacodynamics
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1567-567XFrequency: 6 issues/year

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.

Current Molecular Pharmacology

Showcasing Transformative Discoveries in Molecular Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

ACTA PHARMACOLOGICA SINICA

Fostering Innovation in the Pharmaceutical Landscape
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Empowering Clinicians with Expert Perspectives
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Drug Discoveries and Therapeutics

Unveiling the future of drug development and therapy.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.